Your browser doesn't support javascript.
loading
Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis.
Machado-Alba, Jorge Enrique; Calvo-Torres, Luis Felipe; Gaviria-Mendoza, Andrés; Augusto MejíA-Vélez, César.
Afiliação
  • Machado-Alba JE; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Audifarma S.A., Pereira, Calle 105 No. 14-140, Pereira, Colombia, South America.
  • Calvo-Torres LF; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Audifarma S.A., Pereira, Calle 105 No. 14-140, Pereira, Colombia, South America.
  • Gaviria-Mendoza A; Resident of clinical neurology, Universidad Nacional de Colombia, Bogotá, Colombia, South América.
  • Augusto MejíA-Vélez C; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Audifarma S.A., Pereira, Calle 105 No. 14-140, Pereira, Colombia, South America.
Muscle Nerve ; 56(6): 1041-1046, 2017 Dec.
Article em En | MEDLINE | ID: mdl-28214292
We determined the pyridostigmine prescription pattern in a population of patients with myasthenia gravis (MG). A descriptive cross-sectional study was conducted by using a prescription database of 3.5 million individuals from which patients who had been diagnosed with MG and for whom pyridostigmine had been prescribed were selected. A total of 306 outpatients with MG were found, and 258 were receiving pyridostigmine (mean age 53.0 ± 18.0 years). The calculated prevalence of MG was 86.7 cases per million persons. Monotherapy was used by 53.1% of the patients, prednisolone was used by 21.7%, and 30.2% used other immunomodulators. Medications for other comorbidities were taken by 74.8% of the patients, and 43.4% had prescriptions that could potentially trigger worsening symptoms. Pyridostigmine is being prescribed at doses close to the defined daily doses predominantly as monotherapy. A high proportion of patients were also prescribed a medication that could aggravate their condition, including some that can trigger a myasthenic crisis. Muscle Nerve 56: 1041-1046, 2017.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prescrições de Medicamentos / Brometo de Piridostigmina / Fatores Imunológicos / Miastenia Gravis Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Colombia Idioma: En Revista: Muscle Nerve Ano de publicação: 2017 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prescrições de Medicamentos / Brometo de Piridostigmina / Fatores Imunológicos / Miastenia Gravis Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Colombia Idioma: En Revista: Muscle Nerve Ano de publicação: 2017 Tipo de documento: Article País de publicação: Estados Unidos